title: Structural requirements for the neuroprotective effects of aspirin analogues against N-methyl-D-aspartate and zinc ion neurotoxicity.
abstract: In order to elucidate the structural requirements for the dual neuroprotective activity of aspirin against N-methyl-D-aspartate (NMDA) and zinc ion neurotoxicity, various aspirin analogues and derivatives, modified at the carboxylic group, the acetyl group, and the chain length between the carboxylic acid moiety and phenyl ring, were synthesized. Replacement of the carboxylic acid group with alkyl groups (compounds 2c and 2d) resulted in a dramatic increase in neuroprotective activity against NMDA neurotoxicity, while reduction of the carboxylic acid group to the alcohol (compound 2g) completely abolished this activity. In contrast to NMDA neurotoxicity, compounds that are devoid of the carboxylic acid group did not show any activity against zinc ion neurotoxicity. Replacement of the acetyl group with a propionyl (compound 5a) or butyryl group (compound 5b) did not significantly change the activity against NMDA neurotoxicity, but replacement of the acetyl group with a propionyl group (compound 5a) resulted in a slight decrease in activity against zinc ion neurotoxicity. Compound 12, which has ethylene units between the carboxylic acid moiety and phenyl ring in the structure of aspirin, exhibited greater neuroprotective activity against NMDA neurotoxicity than the compared compounds (aspirin, compound 9 and compound 17), which have different chain lengths. A similar trend was also observed in the neuroprotective activity against zinc ion neurotoxicity. These results indicate that the carboxylic acid group in aspirin is not indispensable for the inhibitory effect against NMDA neurotoxicity, but is essential for the inhibitory effect against zinc ion neurotoxicity. The acetyl group and ethylene unit's distance are favourable for the inhibitory effect against NMDA neurotoxicity as well as zinc ion neurotoxicity.
authors.affiliation: Department of Molecular Science and Technology, Ajou University, Suwon, South Korea.
authors.forename: Ho-Sang
authors.initials: HS
authors.lastname: Moon
authors.forename: Sung-Il
authors.initials: SI
authors.lastname: Nam
authors.forename: Su-Dong
authors.initials: SD
authors.lastname: Kim
authors.forename: DongYeon
authors.initials: D
authors.lastname: Kim
authors.forename: Byoung Joo
authors.initials: BJ
authors.lastname: Gwag
authors.forename: Young Ae
authors.initials: YA
authors.lastname: Lee
authors.forename: Sung-Hwa
authors.initials: SH
authors.lastname: Yoon
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology*; D001241:Aspirin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D002264:Carboxylic Acids / Q000737:chemistry; D002540:Cerebral Cortex / Q000166:cytology / Q000196:embryology; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity*; D007477:Ions; D051379:Mice; D008813:Mice, Inbred ICR; D016202:N-Methylaspartate / Q000633:toxicity*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D015032:Zinc / Q000633:toxicity*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002264:Carboxylic Acids; D018690:Excitatory Amino Acid Agonists; D007477:Ions; D018696:Neuroprotective Agents; D016202:N-Methylaspartate; D015032:Zinc; D001241:Aspirin